JAMA Neuro: Which is more effective?

In order to widely implement the detection of Alzheimer's disease (AD) biomarkers in clinical practice, and to facilitate patient screening and monitoring treatment response in clinical trials, it is necessary to conduct blood-based amyloid β (Aβ) pathology in the brain Screening
.

Recently, experts from the Clinical Memory Institute of the Malmö Department of Clinical Sciences, Lund University, Sweden, conducted a cohort study to compare plasma Aβ 42/40 measured using 8 different Aβ detection methods in the detection of early AD patients’ brain Aβ Performance in abnormal state
.

The results were published in the recent JAMA Neurology journal

JAMA

This study included 182 cognitive accessibility participants and 104 patients with mild cognitive impairment (MCI) from the BioFINDER cohort.
They were enrolled in 3 different hospitals in Sweden and received Aβ positive from 2010 to 2014.
Electron emission tomography (PET) imaging and cerebrospinal fluid (CSF) and plasma collection
.

Using the immunoprecipitation coupled mass spectrometry (IP-MS-WashU) developed by the University of Washington, the antibody -free liquid chromatography mass spectrometry (LC-MS-Arc) developed by Araclon, Roche Diagnostics (IA-Elc), Euroimmun (IA-EI) And the University of Amsterdam Medical Center, ADx Neurosciences and Quanterix (IA-N4PE) immunoassay to measure plasma Aβ42/40

Immune diagnosis

Subsequently, for verification, 122 participants (51 with normal cognition, 51 with MCI, and 20 with AD dementia) were included from the AD neuroimaging initiative, using IP-MS-WashU, IP-MS-Shim, IP- MS-UGOT, IA-Elc, IA-N4PE and IA-Quan detection methods were used for Aβ-PET and plasma Aβ assessment
.

The main result was to evaluate the accuracy of plasma Aβ42/40 quantified using 8 different detection methods to distinguish CSF Aβ42/40 and Aβ-PET abnormal status

In the end, the study included 408 participants
.

In the BioFINDER cohort, the mean (SD) age was 71.

When identifying participants with abnormal CSF Aβ42/40 in the entire cohort, plasma IP-MS-WashU Aβ42/40 (AUC: 0.

The performance of plasma IP-MS-WashU Aβ42/40 was significantly better than IP-MS-UGOT Aβ42/40 and IA-Quan Aβ42/40 (AUC respectively: 0.

Analysis of Aβ42/40 ROC in patients' CSF and the correlation between CSF and plasma Aβ

In addition, plasma IPMS-WashU Aβ42/40 and IPMS-Shim Aβ42/40 have the highest correlation coefficients with CSF Aβ42/40 (r=0.
56-0.
65)
.

The results of BioFINDER have been verified in the AD neuroimaging initiative cohort, in which the performance of IP-MS-WashU measurement was significantly better than that of IP-MS-UGOT, IA-Elc, IA-N4PE and IA-Quan, but IP-MS-WashU Shim test did not

In addition, plasma IPMS-WashU Aβ42/40 and IPMS-Shim Aβ42/40 have the highest correlation coefficients with CSF Aβ42/40 (r=0.

In summary, the results from two independent cohorts indicate that MS-based methods perform better than most immunoassays for plasma Aβ42/40 when detecting brain Aβ pathology

references:

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
JAMA Neurol.
Leave a message here